10times
21 Jul 2021Ended

Project ECHO Diabetes in the Time of COVID-19: DPP-4 Inhibitor, GLP-1 Receptor Agonist, & SGLT Inhibitor Therapies

AboutSpeakersExhibitorsReviewsPhotos

Estimated Turnout

upto 100
Delegates
Based on previous editions

Editions

Jul 2021
+1 more edition

Frequency

Annual
Next edition likely in Jul 2022
Claim event to edit details

This activity will address the urgent needs of patients with type 1 and type 2 diabetes who require complex diabetes treatment in the primary care .. Read more setting in the time of COVID-19 by empowering and increasing the capacity of primary care providers (PCPs) and clinics to safely and effectively manage underserved patients who do not have access to routine specialty care. Led by a nationally/internationally renowned faculty team of diabetes experts (many of whom contribute to/co-author national guideline recommendations), this curriculum will spotlight various aspects of diabetes management for patients at high-risk for poor outcomes during the time of COVID-19. The Stanford University School of Medicine adheres to ACCME Criteria, Standards and Policies regarding industry support of continuing medical education. There are no relevant financial relationships with ACCME-defined commercial interests for anyone who was in control of the content of this activity. After successful completion of all steps, your credit transcript will be available to view and download immediately in MY CE portal.

  • Share your Experience
  • Organizer
Logo Follow Company

Stanford Medicine

USA36 Total Events / 4 Upcoming Events

More Events From The Organizer

\